NEW YORK, NY / ACCESSWIRE / September 21, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.
Oatly Group AB (NASDAQ:OTLY)
Investors Affected: May 20, 2021 - July 15, 2021
A class action has commenced on behalf of certain shareholders in Oatly Group AB. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) Oatly overinflated its gross margins, revenue, capital expenditure, and market share financial metrics; (b) the Company overstated its sustainability practices and impact; (c) the Company exaggerated its growth in China; and (c) as a result of the foregoing, Oatly's statements about its operations, business, and prospects were misleading during the Class Period.
Shareholders may find more information at https://securitiesclasslaw.com/securities/oatly-group-ab-loss-submission-form/?id=19739&from=1
Sesen Bio, Inc. (NASDAQ:SESN)
Investors Affected: December 21, 2020 - August 17, 2021
A class action has commenced on behalf of certain shareholders in Sesen Bio, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Sesen Bio's clinical trial for its cancer treatment product, Vicineum, had more than 2,000 violations of trial protocol, including 215 classified as "major"; (2) three of Sesen Bio's clinical investigators were found guilty of "serious noncompliance," including "back-dating data"; (3) Sesen Bio had submitted the tainted data in connection with the Biologics License Application ("BLA") for Vicineum; (4) Sesen Bio's clinical trials showed that Vicineum leaked out into the body, leading to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury; (5) as a result of the foregoing, the Company's BLA for Vicineum was not likely to be approved; (6) as a result of the foregoing, there was a reasonable likelihood that Sesen Bio would be required to conduct additional trials to support the efficacy and safety of Vicineum; and (7) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Shareholders may find more information at https://securitiesclasslaw.com/securities/sesen-bio-inc-loss-submission-form/?id=19739&from=1
The Honest Company, Inc. (NASDAQ:HNST)
This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Honest common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's May 2021 initial public offering.
A class action has commenced on behalf of certain shareholders in The Honest Company, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) prior to the Initial Public Offering ("IPO"), the Company's results had been significantly impacted by a multimillion-dollar COVID-19 stock-up for products in the Diapers and Wipes category and Household and Wellness category; (2) at the time of the IPO, the Company was experiencing decelerating demand for such products; (3) as a result, the Company's financial results would likely be adversely impacted; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
Shareholders may find more information at https://securitiesclasslaw.com/securities/the-honest-company-inc-loss-submission-form/?id=19739&from=1
The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (212) 537-9430
Fax: (833) 862-7770
SOURCE: The Gross Law Firm